CARL
What one share of Carlsmed holds
Surgical and Medical Instruments and Apparatus
We are a commercial-stage medical technology company pioneering AI-enabled personalized spine surgery solutions with a focus on becoming the standard of care for spine fusion surgery. Our mission is to improve outcomes and decrease the cost of healthcare for spine surgery and beyond.
Carlsmed’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-06-30; the balance sheet is as of 2026-06-30.
| Sales | $2.48 |
|---|---|
| Profit | −$1.43 |
| Capex (buildings and equipment) | $0.02 |
| Free cash flow | −$1.36 |
| Cash and investments | $1.70 |
| Debt | $0.56 |
| Book value | $3.09 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2024 | $6.68 | −$6.11 | $0.04 | −$6.31 | — | −$17.06 |
| 2025 | $3.55 | −$2.12 | $0.05 | −$2.08 | — | $3.72 |